Yuan-hung L. Kuo

123 Ta Pei Road, Niao Sung 833
Kaohsiung, KHQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.

Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: April 12, 2026

Prognostic Significance of Histologic Steatotic Liver Disease in Curatively Resected Non-B, Non-C Hepatocellular Carcinoma.

Prognostic Significance of Histologic Steatotic Liver Disease in Curatively Resected Non-B, Non-C Hepatocellular Carcinoma.

Journal: Cancers

Published: March 26, 2026

Association of HBsAg levels and HBV relapse patterns with HBsAg seroclearance following entecavir or tenofovir cessation.

Association of HBsAg levels and HBV relapse patterns with HBsAg seroclearance following entecavir or tenofovir cessation.

Journal: Biomedical journal

Published: March 09, 2026

Editorial: Regorafenib Plus Nivolumab in Advanced Hepatocellular Carcinoma-A Step Toward Mechanism-Guided Second-Line Therapy.

Editorial: Regorafenib Plus Nivolumab in Advanced Hepatocellular Carcinoma-A Step Toward Mechanism-Guided Second-Line Therapy.

Journal: Alimentary pharmacology & therapeutics

Published: February 19, 2026

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib.

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib.

Journal: The Kaohsiung journal of medical sciences

Published: January 12, 2026

Concurrent Steatotic Liver Disease and Prognosis After Curative Resection of Hepatocellular Carcinoma.

Concurrent Steatotic Liver Disease and Prognosis After Curative Resection of Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: October 29, 2025

Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.

Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 30, 2025

Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis.

Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis.

Journal: Journal of clinical and translational hepatology

Published: August 14, 2025

Pseudoprogression in Hepatocellular Carcinoma During Atezolizumab Plus Bevacizumab Therapy: A Case Report and a Review of Literature.

Pseudoprogression in Hepatocellular Carcinoma During Atezolizumab Plus Bevacizumab Therapy: A Case Report and a Review of Literature.

Journal: Cureus

Published: June 28, 2025

Alternation of the oral, gastric and stool microbiome in patients with reflux esophagitis and Barrett's esophagus.

Alternation of the oral, gastric and stool microbiome in patients with reflux esophagitis and Barrett's esophagus.

Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

Published: March 16, 2025

Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan.

Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan.

Journal: Gut and liver

Published: February 09, 2025

Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Journal: American journal of cancer research

Published: September 28, 2024

Showing 1-12 of 84

Last Updated: 09/26/2026